mRNA-4157/V940in combination with Keytruda receives PRIME scheme designation from EMA
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
Government hospitals like AIIMS, KGMC & many more as per day OPD patients are 18-25 thousand
Lonza supports development and manufacturing of ABL Bio’s bispecific antibody candidate with a complete and integrated end-to-end solution
New York State’s largest health system adopts Philips patient monitoring platform to drive integration and innovation for a better patient and staff experience and improved outcomes
Chief Imam of All India Imam Organization, Dr. Imam Umer Ahmed Ilyas, evinces keen interest in the eradication of Thalassemia & Sickle Cell Disease
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
ProBioGen was able to carry on its rapid growth trajectory by completing a significantly increased number of projects.
70+ CXOs from leading healthcare institutions across India attended the confluence at Mumbai
Subscribe To Our Newsletter & Stay Updated